QLF31907 + docetaxel

QLF31907 + docetaxel is a combination therapy under investigation for advanced malignant tumors. **QLF31907** is a bispecific antibody targeting **programmed death-ligand 1 (PD-L1)** and **4-1BB (CD137)**, developed to restrict 4-1BB activation to the tumor microenvironment, thereby enhancing efficacy and minimizing systemic toxicities. QLF31907 blocks PD-L1 to restore T-cell receptor signaling and acts as a 4-1BB agonist to provide potent costimulatory signals essential for T-cell activation and anti-tumor immune response. **Docetaxel** is a well-established cytotoxic chemotherapeutic that acts by stabilizing microtubules, thereby inhibiting cell division. The combination is being studied to evaluate whether the immunomodulatory effects of QLF31907 synergize with the anti-mitotic action of docetaxel.